Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide in SBS-IF and CIC (STARSnutrition)
NCT04964986Phase 2Completed
- Sponsor
- VectivBio
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of apraglutide in short bowel syndrome (SBS), sponsored by VectivBio. Primary endpoints: Treatment-Emergent Adverse Events and Absolute Change in Absorption of Energy Over Metabolic Balance Periods at Week 48. Started Jun 2021; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04964986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964986.